Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitor Failure
NCT05586841Phase 1Completed
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib and tucidinostat in breast cancer, sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2022; status: completed.
02
Drugs
dalpiciclibtucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05586841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586841.